Previous 10 | Next 10 |
2023-12-28 15:06:23 ET More on AbbVie, Amgen, etc. The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovations Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Bristol Myers Squibb: Too Many Headwinds To Ignore, Despit...
2023-12-27 19:00:20 ET Summary Prevention relapse data from phase 1 study, using TSC-100/TSC-101 for HLA A*02:01 positive AML, MDS, and ALL patients, is expected to be released in 2024. Results from T-Plex [multiple TCR-Ts] targeting patients' solid tumors in phase 1 study are exp...
2023-12-27 10:33:25 ET More on Amgen Amgen: Wonderful Stock At Decent Price Amgen: Bet On Its Breakthrough Drug Amgen Inc. (AMGN) Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript) Amgen says FDA declined full approval for lung cancer drug...
2023-12-26 09:29:27 ET More on Amgen Amgen: Wonderful Stock At Decent Price Amgen: Bet On Its Breakthrough Drug Amgen Inc. (AMGN) Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript) Amgen upgraded by BMO on underappreciated opportunity in o...
AMGEN PROVIDES REGULATORY UPDATE ON STATUS OF LUMAKRAS® (SOTORASIB) PR Newswire FDA Has Issued New Postmarketing Requirement LUMAKRAS Dosing Confirmed at 960 mg Once-Daily for Patients With KRAS G12C-Mutated NSCLC Under Accelerated Approval THOUSAND ...
2023-12-25 10:03:02 ET Summary I discuss my investment and trading strategies before and after March 2022. I highlight the importance of trade income, capital gains, dividend collection, and tax harvesting in my investment approach. I want to see the Bull Plateau (or Bear-Mark...
2023-12-23 04:24:25 ET Summary Bristol Myers Squibb is resorting to larger M&A deals to drive new product sales and combat the challenges it faces with the loss of exclusivity of its top-selling drug Revlimid. The company's 2023 outlook is tough, with stagnation and a decline ...
2023-12-23 04:18:53 ET Summary AbbVie and GSK are both solid investment choices in the biopharmaceutical industry. AbbVie's financials and forward outlook show strong performance alongside solid partnerships, which hint at growth potential. GSK's current financials, product la...
2023-12-23 01:00:32 ET Summary SCHD is a dividend-focused ETF that has provided substantial dividend growth with a 5-year dividend CAGR of 13%. It has outperformed similar funds over the past 5 years and has a low expense ratio of 0.06%. The fund has a conservative approach an...
2023-12-21 13:56:16 ET More on CRISPR Therapeutics Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed CRISPR Gene Editing: Intellia Vs. Crispr Therapeutics Crispr Therapeutics: The Party Is Over (Rating Downgrade) Vertex sickl...
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 10:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-15 07:58:00 ET Can a biotechnology company pay a generous dividend in 2024? The answer is definitely yes, as Amgen (NASDAQ: AMGN) is evidently unafraid to reward its loyal shareholders with quarterly cash payments. Just as importantly, Amgen is a recent revenue growe...